Moisand Fitzgerald Tamayo LLC held its stake in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, Holdings Channel reports. The firm owned 2,114 shares of the biopharmaceutical company’s stock at the end of the first quarter. Moisand Fitzgerald Tamayo LLC’s holdings in Celgene Corporation were worth $263,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Motco raised its position in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Carroll Financial Associates Inc. raised its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. raised its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Reilly Financial Advisors LLC raised its position in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares during the period. Finally, WealthTrust Arizona LLC raised its position in Celgene Corporation by 26.1% in the first quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 251 shares during the period. Institutional investors and hedge funds own 78.16% of the company’s stock.

Celgene Corporation (CELG) opened at 134.27 on Wednesday. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $136.12. The firm has a market cap of $104.84 billion, a PE ratio of 50.42 and a beta of 1.89. The stock has a 50 day moving average of $126.63 and a 200 day moving average of $122.08.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.21. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. Celgene Corporation’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 EPS. On average, equities research analysts anticipate that Celgene Corporation will post $7.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (NASDAQ:CELG) Position Maintained by Moisand Fitzgerald Tamayo LLC” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/celgene-corporation-nasdaqcelg-position-maintained-by-moisand-fitzgerald-tamayo-llc/1450992.html.

A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and set a $151.00 price target on the stock in a research report on Tuesday. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a research note on Friday, July 14th. Vetr downgraded shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $149.76 target price for the company. in a research note on Friday, July 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a research note on Tuesday, July 11th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $153.00 target price on shares of Celgene Corporation in a research note on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $141.92.

In other news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders sold a total of 237,005 shares of company stock valued at $31,515,142 in the last quarter. 0.95% of the stock is currently owned by company insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.